You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Bristol Myers Squibb’s psoriasis med hits the mark in phase III

Bristol Myers Squibb’s tyrosine kinase 2 (TYK2) inhibitor deucravacitinib outperformed Amgen’s Otezla in a phase III psoriasis study, the pharma company revealed yesterday.